5 Discussion SID is a frequent complication of GCs therapy, with limited guidance regarding optimal management strategies
This price on the initial doses is currently valid through March 2026
and received advisory/consulting fees and/or other support from AbbVie, Altimmune, AstraZeneca, Bayer, Betagenon AB, BIOIO, Biomea Fusion, Boehringer Ingelheim, Carmot Therapeutics, Cytoki Pharma, Eli Lilly, Intercept, Janssen/Johnson & Johnson, Juvena Therapeutics, Keros Therapeutics, Mediflix, Merck, Metsera, Novo Nordisk, PharmaVentures, Pfizer, Regeneron Pharmaceuticals, Sanofi, Shionogi, Structure Therapeutics, Target RWE, Terns Pharmaceuticals, The Comm Group, WebMD, and Zealand Pharma
Most compounded preparations tolerate ambient conditions between 59F and 86F for the active treatment period, though cooler is always preferable
Standardized mean differences (SMDs) were presented, and SMD 0.1 was considered a meaningful difference